We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Diagnostic Test for Congenital Syphilis Could Enable Immediate Treatment

By LabMedica International staff writers
Posted on 15 Sep 2023
Print article
Image: Few sensitive diagnostic tests exist to determine if a baby has developed congenital syphilis (Photo courtesy of 123RF)
Image: Few sensitive diagnostic tests exist to determine if a baby has developed congenital syphilis (Photo courtesy of 123RF)

Newborns with congenital syphilis may suffer from issues like bone damage, severe anemia, enlarged liver and spleen, jaundice, nerve issues leading to blindness or hearing loss, meningitis, or skin conditions. The severity of these health issues in the baby largely depends on whether the mother has received timely treatment for syphilis. At present, there are no sensitive diagnostic tests to confirm if a newborn has congenital syphilis. The current diagnostic approach is based on whether the mother has been treated for syphilis or if the baby shows any symptoms of the disease, along with abnormally high syphilis serology labs. As a result, doctors are forced to go through a checklist to assess if the mother has the infection and monitor the newborn for months to establish their infection status. Now, a molecular diagnostic test being developed for the detection of congenital syphilis could enable physicians to begin immediate treatment for newborns.

Researchers from UTHealth Houston (Houston, TX, USA) are working on creating a molecular diagnostic test that can quickly identify congenital syphilis, enabling immediate treatment for the affected newborns. The team is also planning a multicenter study that will examine the neurodevelopmental outcomes in babies born with the disease. This is particularly important as 60% of untreated babies born with syphilis suffer from neurodevelopmental issues.

“Our goal is to create a test for syphilis that is effective, so we can do immediate treatment,” said Irene Stafford, MD, at UTHealth Houston who is the principal investigator. “This test could be an incredible step in treating and diagnosing congenital syphilis.”

Related Links:
UTHealth Houston 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.